Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Research programme: Rho-associated kinase inhibitors - Kadmon Pharmaceuticals

Drug Profile

Research programme: Rho-associated kinase inhibitors - Kadmon Pharmaceuticals

Alternative Names: KD 045

Latest Information Update: 06 Dec 2018

Price : $50 *
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Surface Logix
  • Developer Kadmon Pharmaceuticals; Surface Logix
  • Class Antineoplastics; Antirheumatics; Immunotherapies; Small molecules
  • Mechanism of Action Rho-associated kinase inhibitors; STAT3 transcription factor modulators
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity Yes

Highest Development Phases

  • Preclinical Autoimmune disorders; Fibrosis; Graft-versus-host disease; Lupus vulgaris
  • No development reported Cancer; Glaucoma; Metabolic disorders

Most Recent Events

  • 07 Mar 2019 Kadmon Holdings plans a clinical trial for Fibrotic diseases in second half of 2019
  • 06 Dec 2018 Preclinical development is ongoing for Fibrosis in USA
  • 29 Nov 2018 Kadmon announces intention to submit IND application for KD 045 in the second half of 2019
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top